Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

@8thKingofRome @FrankHulskof @maddstone1 @dhovekamp42 @MitchellReed09 How many pts with EGFR mut responded to PD1? 0 none of the patients bearing EGFR mutations responded to pembrolizumab. trial enrolment was halted due to lack of efficacy after 11 of the

レジ用周術期薬物 [2-1]術後補助療法にIOを入れる ・術後に残存する顕微鏡的病変に対して、術後のIOが持続的な免疫学的反応を可能にするとされている。 ・課題1：EGFR変異を有する患者は、一般的には免疫療法の有用性が低いとされる https://t.co/kXM8UpvqgO https://t.co/MuL8uiKUQF

📣 Check out this article on current challenges and new strategies for #Immunotherapy in EGFR-mutant #LungCancer - By Kenneth K. W. To et al Read the full #OpenAccess article 👉 https://t.co/Qrmyl3jPgb #LungCancer #LCsm #ThoracicOnology #Oncology https://t

RT @filimasini: Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies https://t.co/mVbT7Q6PEa